4.6 Article

Comparative Outcomes of Salvage Retzius-Sparing versus Standard Robotic Prostatectomy: An International, Multi-Surgeon Series

Journal

JOURNAL OF UROLOGY
Volume 206, Issue 5, Pages 1184-1191

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/JU.0000000000001939

Keywords

prostatic neoplasms; prostatectomy; neoplasm recurrence, local

Funding

  1. Frederick J. and Theresa Dow Wallace Fund of the New York Community Trust
  2. NCI [R01 CA241758]
  3. [PCORI CER-2019C1-15682]
  4. [PCORI CER-2019C2-17372]

Ask authors/readers for more resources

Salvage Retzius-sparing robotic assisted radical prostatectomy (SRS-RARP) showed improved urinary function outcomes compared to salvage standard robotic assisted radical prostatectomy (SS-RARP), with better continence rates, lower pads per day, and earlier return to continence. There were no significant differences in complication rates or oncologic outcomes between the two procedures. Increased utilization of SRS-RARP may be warranted for managing men who fail nonsurgical primary treatment for prostate cancer.
Purpose: Salvage radical prostatectomy is rare due to the risk of postoperative complications. We compare salvage Retzius-sparing robotic assisted radical prostatectomy (SRS-RARP) with salvage standard robotic assisted radical prostatectomy (SS-RARP). Materials and Methods: A total of 72 patients across 9 centers were identified (40 SRS-RARP vs 32 SS-RARP). Demographics, perioperative data, and pathological and functional outcomes were compared using Student's t-test and ANOVA. Cox proportional hazard models and Kaplan-Meier curves were constructed to assess risk of incontinence and time to continence. Linear regression models were constructed to investigate postoperative pad use and console time. Results: Median followup was 23 vs 36 months for SRS-RARP vs SS-RARP. Console time and estimated blood loss favored SRS-RARP. There were no differences in complication rates or oncologic outcomes. SRS-RARP had improved continence (78.4% vs 43.8%, p <0.001 for 0-1 pad, 54.1% vs 6.3%, p <0.001 for 0 pad), lower pads per day (0.57 vs 2.03, p <0.001), and earlier return to continence (median 47 vs 180 days, p=0.008). SRS-RARP was associated with decreased incontinence defined as >0-1 pad (HR 0.28, 95% CI 0.10-0.79, p=0.016), although not when defined as >0 pad (HR 0.56, 95% CI 0.31-1.01, p=0.053). On adjusted analysis SRS-RARP was associated with decreased pads per day. Lymph node dissection and primary treatment with stereotactic body radiation therapy were associated with longer console time. Conclusions: SRS-RARP is a feasible salvage option with significantly improved urinary function outcomes. This may warrant increased utilization of SRS-RARP to manage men who fail nonsurgical primary treatment for prostate cancer.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available